Company: LNAI
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001731122-25-000765
Chunk: 103

Company: Lunai Bioworks Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 8
Chunk 103
---
     (2,904,909)

    Goodwill 
     159,464,040 
  
    Total Consideration 
    $156,559,131 

The goodwill
recognized is attributable primarily to expected synergies and the assembled workforce of Gedi Cube. None of the goodwill is expected
to be deductible for income tax purposes.

The fair
values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation
methodology used for the intangible assets acquired makes use of Level 3 inputs.

    22

Consolidated unaudited pro forma information: 

The following consolidated pro
forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2023 for the statement of operations for the nine
month period ended March 31, 2024. These amounts have been estimated after applying the Company’s accounting policies:

    Schedule of consolidated proforma information 

    Three months ended March 31, 2024 
    Nine months ended March 31, 2024
  
    Revenues 
    $—  
    $— 
  
    Net loss 
    $(15,842,575) 
    $(67,967,173)

The unaudited
pro forma results are presented for informational purposes only and are not necessarily indicative of what the actual results of operations
would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of
operations.

NOTE 11 — SUBSEQUENT EVENTS 

On February
26, 2025, Renovaro, Inc., a Delaware corporation (“Renovaro”), entered into an Agreement and Plan of Merger (the “Merger
Agreement”) with Renovaro Acquisition Sub, a Delaware corporation and wholly owned subsidiary of Renovaro (“Merger
Sub”), and Biosymetrics, Inc., a Delaware corporation (“Biosymetrics”), pursuant to which Renovaro agreed
to acquire Biosymetrics pursuant to the merger of Merger Sub with and into Biosymetrics, with Biosymetrics as the surviving corporation
and a wholly owned subsidiary of Renovaro (the “Transaction”). On April 8, 2025, Renovaro consummated the Transaction
and issued 15.0 million shares of Renovaro’s common stock, par value $0.0001 per share (the “Shares”), to the
former stockholders of Biosymetrics in accordance with